EMR
TEVA icon

Errol M. Rudman’s Teva Pharmaceuticals TEVA Stock Holding History

Errol M. Rudman’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$880K – 43
2017
Q3 		$880K Buy
+50,000
New +$1.13M 0.51% 33

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Errol M. Rudman's TEVA Position: Q4 2017 in Review

Errol M. Rudman sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 50,000 shares — an estimated $880K sold.

Errol M. Rudman first reported a position in TEVA in Q3 2017 and held it in 1 quarter. The position peaked at $880K in Q3 2017. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Errol M. Rudman reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Errol M. Rudman sold 50,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $880K.
  • Errol M. Rudman first reported a position in Teva Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Errol M. Rudman's Teva Pharmaceuticals position peaked at $880K in Q3 2017.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Errol M. Rudman's 13F filing for Q4 2017, filed 14 Feb 2018.